Connective Tissue Matrix for Rotator Cuff Tendinopathy

Launched by ALLEGHENY SINGER RESEARCH INSTITUTE (ALSO KNOWN AS ALLEGHENY HEALTH NETWORK RESEARCH INSTITUTE) · Nov 29, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating whether a single injection of a treatment called CTM Boost is as effective as a single injection of platelet-rich plasma (PRP) for helping people with rotator cuff tendinopathy, a common cause of shoulder pain. The goal is to see which treatment better reduces symptoms like pain and discomfort in the shoulder.

To participate in this study, you need to be between 18 and 80 years old and have been diagnosed with rotator cuff tendinopathy. It's also important that your doctor thinks either a CTM or PRP injection is the right treatment for you and that you're willing to receive the injection. However, if you have certain shoulder conditions, a history of shoulder surgery recently, or other medical issues that could affect healing, you may not be eligible. If you join the trial, you can expect to receive one of these injections and help researchers understand how well each treatment works for patients like you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18-80 years old with rotator cuff tendinopathy
• • A PRP or CTM-type injection was determined by the clinician to be the proper medical treatment course and patient is willing to undergo the injection
• Exclusion Criteria:
• • Patients with adhesive capsulitis
• • Patients with acromio-clavicular joint impingement, retracted tears, significant labral lesions or significant glenohumeral arthrosis
• • Patients with joint instability
• • History of shoulder surgery or corticosteroid injection in the past 3 months
• • Patients with any medical conditions that affect healing, such as end-stage renal disease or uncontrolled diabetes